Nuclide Therapeutics

London, United Kingdom

Nuclide Therapeutics provides radiopharmaceutical medicines that combine nuclear medicine and biotechnology.

$6.7M raised

Sep 2025

Seed

Health Care Pharmaceutical Therapeutics

Top Investors

Marathon BeteiligungsWellcome Trust

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Nuclide Therapeutics

How much funding has Nuclide Therapeutics raised?

Nuclide Therapeutics has raised $6.7M in total funding. The most recent round was Seed. The last funding was announced in September 2025.

Who are Nuclide Therapeutics's investors?

Nuclide Therapeutics's investors include Marathon Beteiligungs, Wellcome Trust.

Where is Nuclide Therapeutics headquartered?

Nuclide Therapeutics is headquartered in London, United Kingdom.

What does Nuclide Therapeutics do?

Nuclide Therapeutics provides radiopharmaceutical medicines that combine nuclear medicine and biotechnology.

What stage is Nuclide Therapeutics at?

Nuclide Therapeutics is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 22, 2025.

MLA

"Nuclide Therapeutics — Funding & Investors." VCBacked, September 22, 2025, https://www.vcbacked.co/company/nuclide-therapeutics. Accessed June 17, 2026.

APA

VCBacked. (2025). Nuclide Therapeutics — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/nuclide-therapeutics

Wikipedia (cite web)

{{cite web |title=Nuclide Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nuclide-therapeutics |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 22, 2025.